Orion M. Howard

Statistics

Publications

Citations

H-Index

Active since

2002

Affiliations

Orion M. Howard is an author at Dana-Farber Cancer Institute specializing in medicine, cancer pharmacology, and chemotherapy in hematologic malignancies.

Publications per year

2002–2017

Publications

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Rituximab and CHOP Induction Therapy for Newly Diagnosed Mantle-Cell Lymphoma: Molecular Complete Responses Are Not Predictive of Progression-Free Survival

Orion M. Howard, John G. Gribben, Donna Neuberg et al. · Journal of Clinical Oncology · 2002 · 347 citations

Medicine, Hematology, Oncology +17

Seventy-Two Hour Continuous Infusion Flavopiridol in Relapsed and Refractory Mantle Cell Lymphoma

Thomas S. Lin, Orion M. Howard, Donna Neuberg et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2002 · 75 citations

Medicine, Pharmacology, Pharmacotherapy +17

Parvovirus B19 Infection

Shirley Chen, Orion M. Howard · New England Journal of Medicine · 2004 · 26 citations

Life Sciences, Infectious Diseases, Microbiology +10

1–4 of 4